Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Pulmatrix Raises US$6.5 Million In Extended Series B1 Financing 11
Partnerships 12
Capsugel Enters into Agreement with Pulmatrix 12
Pulmatrix Enters Into Alliance with Celdara Medical 13
Pulmatrix Enters into Co-Development Agreement with Mylan 14
Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15
Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16
Merger 17
Ruthigen Merges with Pulmatrix 17
Licensing Agreements 18
Vectura Group Enters into Licensing Agreement with Pulmatrix 18
Pulmatrix Enters into Licensing Agreement with RespiVert 19
Oculus Innovative Amends the Licensing Agreement With Ruthigen 20
Equity Offering 22
Pulmatrix Prices Public Offering of Units for USD15.2 Million 22
Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24
Pulmatrix Raises USD5 Million in Private Placement of Shares 25
Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26
Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28
Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30
Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For US$20.3 Million 31
Pulmatrix Inc – Key Competitors 33
Pulmatrix Inc – Key Employees 34
Pulmatrix Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
May 11, 2018: Pulmatrix Reports Q1 2018 Results 36
Mar 13, 2018: Pulmatrix Announces 2017 Financial Results 37
Nov 09, 2017: Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials 38
Aug 04, 2017: Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials 40
May 05, 2017: Pulmatrix Reports Q1 2017 Financial Results 42
Mar 10, 2017: Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline 43
Corporate Communications 45
Jun 15, 2017: Amit D. Munshi Joins Pulmatrix’s Board of Directors 45
May 03, 2017: Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer 46
Mar 27, 2017: Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board 47
Product News 48
10/30/2017: Pulmatrix Appoints Dr. James Roach as Chief Medical Officer 48
Product Approvals 49
Oct 03, 2017: Pulmatrix Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” (QIDP) Designation from the FDA 49
Jan 17, 2017: Pulmatrix Drug Candidate Receives “Qualified Infectious Disease Product” Designation from the FDA 50
Clinical Trials 51
Oct 31, 2017: Pulmatrix Presents at the North American Cystic Fibrosis Conference 51
Oct 30, 2017: Pulmatrix Provides Update on its Anti-Inflammatory Drug Candidate PUR1800 52
Sep 05, 2017: Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections 53
Other Significant Developments 54
Sep 19, 2017: CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
Pulmatrix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pulmatrix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pulmatrix Raises US$6.5 Million In Extended Series B1 Financing 11
Capsugel Enters into Agreement with Pulmatrix 12
Pulmatrix Enters Into Alliance with Celdara Medical 13
Pulmatrix Enters into Co-Development Agreement with Mylan 14
Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15
Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16
Ruthigen Merges with Pulmatrix 17
Vectura Group Enters into Licensing Agreement with Pulmatrix 18
Pulmatrix Enters into Licensing Agreement with RespiVert 19
Oculus Innovative Amends the Licensing Agreement With Ruthigen 20
Pulmatrix Prices Public Offering of Units for USD15.2 Million 22
Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24
Pulmatrix Raises USD5 Million in Private Placement of Shares 25
Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26
Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28
Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30
Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For US$20.3 Million 31
Pulmatrix Inc, Key Competitors 33
Pulmatrix Inc, Key Employees 34
Pulmatrix Inc, Subsidiaries 35
List of Figures
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9